PhRMA

Representing America’s biopharma & biotech companies. Shaping policy so science thrives & patients benefit.

[PhRMA @PhRMA]

When your child is sick, time is everything. ⏳

Americans get new medicines 3 years faster than other countries. But if Washington copies other countries’ price control policies, we could be forced to wait, too.

Our new ad highlights what's at stake. Watch now:

[PhRMA @PhRMA]

85% of insured Americans say they would be likely to purchase medicines directly from manufacturers if it could help lower prescription drug costs.

More options and greater transparency can help support patients access and afford their medicines.

Learn more at https://t.co/nhV8bCJYOh.

[PhRMA @PhRMA]

On World Sickle Cell Day, we recognize the promise of cell and gene therapies for patients living with sickle cell disease. These innovative treatments are expanding options and helping build a brighter future for patients and families.

[PhRMA @PhRMA]

America's Medicines ya está disponible en español para que más pacientes y sus cuidadores encuentren información sobre recursos que podrían ayudarles a acceder a medicamentos recetados.

[PhRMA @PhRMA]

Patients in other high-income countries have access to less than half as many new medicines across major therapy areas than in the US.

When policies undervalue innovation, patients face fewer treatment options and can face longer waits for new medicines.

[PhRMA @PhRMA]

Melissa was diagnosed with a brain tumor, but fast access to medical innovation saved her life.

Americans get new medicines 3 years faster than other countries. America needs to continue to lead the world in medicine development, so moms like Melissa can have more tomorrows.

[PhRMA @PhRMA]

It's time to modernize 340B.

A rebate model would improve accountability and transparency while preserving patient access and support for safety net providers.

Here’s what you need to know ▶️ https://t.co/LNqL7klaO1

[PhRMA @PhRMA]

The U.S. is at risk of losing its lead in medical innovation. While we debate MFN price controls, China is accelerating clinical trials and expanding its leadership in oncology and immunotherapy.

If we hand over the future of medicine to China, patients will pay the price.

Read more here: https://t.co/wo3m52znm2

[PhRMA @PhRMA]

77% of insured Americans said they were interested in learning more about new websites that allow patients to purchase medicines directly from manufacturers.

Can you relate? Visit America’s Medicines to see how greater transparency helps patients navigate health care decisions.

[PhRMA @PhRMA]

This week, biopharmaceutical researchers met with over 175 policymaker offices.

We are incredibly grateful to the researchers who lent their voices to protect the ecosystem that enables life-saving science. #PhRMAFlyIn26

https://t.co/RqnoTVTUjk

[PhRMA @PhRMA]

Today, our researchers are heading to Capitol Hill to meet directly with lawmakers and congressional staff to advocate for the pro-innovation policies that ensure America stays a global leader in medical discovery. #PhRMAFlyIn26

[PhRMA @PhRMA]

Our researchers are convening in DC today for #PhRMAFlyIn26!

Tomorrow, they will go to Capitol Hill to advocate for the policies needed to deliver new treatments to patients.

Follow along on Instagram
>>> https://t.co/YpUvuhg2uT

[PhRMA @PhRMA]

Patients in other high-income countries have access to just 36% of new medicines. U.S. patients have access to 88%.

That gap is driven by policy choices that delay or restrict access.

We need policies that support innovation and ensure patients get the treatments they need.

[PhRMA @PhRMA]

@KyowaKirin_US is expanding U.S. manufacturing capabilities to strengthen supply chain resilience, support patient access and advance next-generation treatments for rare diseases.

[PhRMA @PhRMA]

Today is National Cancer Survivors Day, a time to celebrate life, honor resilience and look ahead at the incredible science bringing hope to millions.

Hear from some of our companies on the future of cancer treatments and the investments being made to deliver new treatments and new tomorrows for so many patients.

https://t.co/jUuXUPUV1T

[PhRMA @PhRMA]

Cell and gene therapies are changing the future of medicine.

But many Medicare patients still face barriers to accessing these innovative treatments. Our health care system must keep pace with innovation so patients can benefit from these breakthroughs.

[PhRMA @PhRMA]

Hospitals are converting to nonprofits to tap 340B revenue.

This begs the question: is this massive federal program supporting patients or being exploited to boost hospital profits? https://t.co/fAYvbx41sG

[PhRMA @PhRMA]

June is Alzheimer’s & Brain Awareness Month — a time to recognize the millions of patients, families and caregivers impacted by Alzheimer’s disease and renew our commitment to advancing new treatments and cures.

For decades, Alzheimer’s was considered one of medicine’s greatest challenges. Today, scientific innovation is changing what’s possible.

[PhRMA @PhRMA]

As policymakers are considering harmful price control policies in the form of Most Favored Nation pricing, patients and caregivers are voicing their concerns.

Hear what they have to say: https://t.co/59AzPV27AN

[PhRMA @PhRMA]

On average, it takes 10 to 15 years and $2.6 billion to develop just one medicine, and only 12% of medicines entering clinical trials are successful in getting FDA approval.

IP protections, including patents, empower innovators to take on significant risks to develop the best medicines in the world.

https://t.co/lHbqXrRLsu